An open treatment trial of duloxetine in elderly patients with dysthymic disorder

Objective: We evaluated the efficacy and side effects of the selective serotonin and norepinephrine reuptake inhibitor antidepressant duloxetine in older adults with dysthymic disorder. Methods: Patients ≥ 60 years old with dysthymic disorder received flexible dose duloxetine 20–120 mg daily in an o...

Full description

Bibliographic Details
Published in:	SAGE Open Medicine
Main Authors:	Nancy Kerner, Kristina D’Antonio, Gregory H Pelton, Elianny Salcedo, Jennifer Ferrar, Steven P Roose, DP Devanand
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-05-01
Online Access:	https://doi.org/10.1177/2050312114533536

Similar Items

Use of aripiprazole in dysthymic disorders. Purposely a case
by: N. Ogando Portilla, et al.
Published: (2023-03-01)

L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine
by: Giuseppe Bersania, et al.
Published: (2015-02-01)

Research Progress of Central and Peripheral Corticotropin-Releasing Hormone in Irritable Bowel Syndrome with Comorbid Dysthymic Disorders
by: Yi Feng Liang, et al.
Published: (2024-05-01)

Protective Role of L-3-n-Butylphthalide in Cognitive Function and Dysthymic Disorders in Mouse With Chronic Epilepsy
by: Xiaowen Ye, et al.
Published: (2018-07-01)

Duloxetine-Induced Hyponatremia in an Elderly Male Patient with Treatment-Refractory Major Depressive Disorder
by: Ching-Fang Sun, et al.
Published: (2019-01-01)

The response time to emotional stimuli (including facial expressions photos) during the fMRI scanning in affective disorders: mild and moderate depression and dysthymic disorder
by: M. Ye. Mel’nikov, et al.
Published: (2018-03-01)

Duloxetine in panic disorder with somatic gastric pain
by: Preve M, et al.
Published: (2013-11-01)

Treatment of major depressive disorder (MDD) or dysthymic disorder (DD) in spinal cord injury (SCI) patients: a protocol for a systematic review and network meta-analysis
by: Hyun-Jin Kim, et al.
Published: (2022-12-01)

Controlled randomized clinical trial of spirituality integrated psychotherapy, cognitive-behavioral therapy and medication intervention on depressive symptoms and dysfunctional attitudes in patients with dysthymic disorder
by: Amrollah Ebrahimi, et al.
Published: (2013-01-01)

Continuation treatment of major depressive disorder: is there a case for duloxetine?
by: Trevor&nbsp;R Norman, et al.
Published: (2010-02-01)

Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: an open-label study
by: Watkin John G, et al.
Published: (2004-12-01)

Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder
by: Maria Rosaria Anna Muscatello, et al.
Published: (2019-10-01)

Treatment of Fibromyalgia - duloxetine or pregabalin?
by: Magdalena Bujak, et al.
Published: (2025-04-01)

Structure of racemic duloxetine hydrochloride
by: Mohan M. Bhadbhade, et al.
Published: (2023-05-01)

Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder
by: Robinson Rebecca L, et al.
Published: (2011-01-01)

Effect of the dual action antidepressant duloxetine in the treatment of functional disorders of the gastrointestinal tract
by: G. M. Dyukova, et al.
Published: (2014-12-01)

The effect of duloxetine on stress urinary incontinence
by: Nahid Lorzadeh, et al.
Published: (2024-05-01)

Efficacy of Hash value in infrared thermogram in assessment of duloxetine for persistent somatoform pain disorder
by: ZENG Shuang, et al.
Published: (2023-10-01)

Effect of duloxetine on changes in serum proinflammatory cytokine levels in patients with major depressive disorder
by: Wenfan Gao, et al.
Published: (2024-06-01)

Duloxetine-induced rapid eye movement sleep behavior disorder: a case report
by: Lu Tan, et al.
Published: (2017-11-01)

Effectiveness of Duloxetine for Postsurgical Chronic Neuropathic Disorders after Spine and Spinal Cord Surgery
by: Osahiio Tsuji, et al.
Published: (2021-10-01)

Opsoclonus-myoclonus syndrome secondary to duloxetine toxicity
by: J. Trigo López, et al.
Published: (2021-04-01)

Acute generalized exanthematous pustulosis induced by duloxetine
by: Numa Deydier, et al.
Published: (2023-06-01)

Visual hallucination induced by duloxetine use: a male case diagnosed with generalized anxiety disorder
by: Kemal Utku Yazici, et al.
Published: (2018-07-01)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
by: Harada E, et al.
Published: (2016-01-01)

Efficacy of duloxetine in treating temporomandibular joint disorder: a systematic review with bayesian meta-analysis
by: Sasidharan Sivakumar, et al.
Published: (2025-08-01)

Clinical effect of flunarizine combined with duloxetine in the treatment of chronic migraine comorbidity of depression and anxiety disorder
by: Junliang Zhu, et al.
Published: (2022-08-01)

Simple and Practical Method for the Quantitative High-Sensitivity Analysis of N‑Nitroso Duloxetine in Duloxetine Drug Products Utilizing LC-MS/MS
by: Shohei Fukuda, et al.
Published: (2024-03-01)

Reversible cycloplegia caused by duloxetine: a case report
by: Rabia Nazik Yüksel, et al.
Published: (2017-07-01)

Duloxetine-Induced Sleep Bruxism and Tooth Fracture in Fibromyalgia
by: İsmail Tunçekin, et al.
Published: (2024-12-01)

Use of dual action inhibitor (duloxetine) in diabetic neuropathy
by: Irina Vladimirovna Gur'eva
Published: (2009-03-01)

Comparison of Efficacy of Duloxetine Versus Amitriptyline in Fibromyalgia Patients
by: Saira Tahir, et al.
Published: (2024-12-01)

Clinical pearls for the management of duloxetine patients with medical comorbidities
by: Megan O’Connell, PharmD, BCPP, et al.
Published: (2024-12-01)

Comparing the effectiveness of pregabalin and duloxetine in the management of neuropathic pain
by: Rojgar Hamed Ali, et al.
Published: (2025-04-01)

New treatment options for fibromyalgia: critical appraisal of duloxetine
by: Nurcan &Uuml;&ccedil;eyler, et al.
Published: (2008-06-01)

A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
by: Daniela Rodrigues-Amorim, et al.
Published: (2020-10-01)

Spinal cord vascular degeneration impairs duloxetine penetration
by: M. E Da Vitoria Lobo, et al.
Published: (2023-05-01)

Tumor growth activity of duloxetine in Ehrlich carcinoma in mice
by: Ed Carlos Rey Moura, et al.
Published: (2018-07-01)

Repurposing Duloxetine as a Potent Butyrylcholinesterase Inhibitor: Potential Cholinergic Enhancing Benefits for Elderly Individuals with Depression and Cognitive Impairment
by: Taher Darreh-Shori, et al.
Published: (2024-08-01)

Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
by: Xinyuan Li, et al.
Published: (2018-01-01)